<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357562</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2016/28</org_study_id>
    <nct_id>NCT03357562</nct_id>
  </id_info>
  <brief_title>MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis</brief_title>
  <acronym>CFMR-lung</acronym>
  <official_title>MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the diagnostic sensitivity of MRI to detect changes in
      Helbich-Bhalla scoring over time in patients with cystic fibrosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CF) is caused by the cystic fibrosis transmembrane conductance regulator
      (CFTR) gene mutation and represents one of the most frequent and lethal inherited disease in
      Caucasian. However, thanks to better treatments that slow down the progression of pulmonary
      disease, the median life expectancy has reached 41 years and there are nowadays more CF
      patients older than 18-year-old than younger. Chronic lung disease is the main manifestation
      and represents more than 90% of CF morbidity and mortality. However, there is a need for
      biomarkers more sensitive than clinical and functional findings for a personalized management
      of patients. Computed tomography (CT), owing to its high spatial resolution and contrast, is
      the standard of reference in imaging for depicting lung structural alterations. But CT is an
      ionizing technique, rising concern in cancer risk associated to cumulated radiation dose. To
      date, Magnetic Resonance Imaging (MRI) is a radiation-free technique which has been
      demonstrated to add meaningful functional information that cannot be reached using CT. Recent
      advances in 3-dimensional ultra-short echo time (3D-UTE) imaging have been shown promising to
      improve lung MR imaging quality. A clear delineation between airway wall and lumen was
      obtained, thanks to submillimeter voxel size, enabling readers to estimate both bronchial
      thickening and dilatation with very good concordance with CT, independently from the
      magnitude of score. The combination of pulse sequence may rather benefit from the potential
      of MRI to get more complete insight into inflammatory processes by combining several
      contrasts, as compared to other ionizing methods. Novel MR methods have been shown promising
      in assessing lung changes with high resolution and therefore could be proposed instead of CT
      for radiation- free repeated, life-long follow-up
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of MRI to detect lung changes</measure>
    <time_frame>Month 36</time_frame>
    <description>deterioration or improvement measured by the Helbich-Bhalla scoring with CT as gold standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of MRI to Helbich-Bhalla scoring change</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Sensitivity of MRI to Helbich-Bhalla scoring change in various subgroups of patients according to age, centers and MR scan manufacturers, and new treatment drug use (Ivacaftor/lumicaftor: Orkambi Ø or Ivacaftor : Kalydeco Ø ) from CT and MR examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT / MR concordance</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Concordance between CT and MR in amplitude of Helbich-Bhalla scoring variations at M0 and M36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of the 3D-UTE MR sequence</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Sensitivity of the 3D-UTE MR sequence alone to detect change in Helbich-Bhalla scoring as compared to CT performed at M0 and M36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging quality of the 3D-UTE MR</measure>
    <time_frame>Month 0, Month 12, Month 24 and Month 36</time_frame>
    <description>using a likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between a specific Helbich-Bhalla MR score and the amplitude of change</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Correlation between a specific Helbich-Bhalla MR score with clinical and functional data, and concordance with the amplitude of change between M0 and M36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of a lung MR protocol</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Accuracy of a lung MR protocol including T1-weighted and T2-weighted sequences to diagnose allergic broncho-pulmonary aspergillosis (ABPA) in CF patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility in detecting lung structural abnormality</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>MR and CT reproducibility in detecting lung structural abnormality at the segmental level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility in overall Helbich-Bhalla scoring</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>MR and CT reproducibility in overall Helbich-Bhalla scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between Helbich-Bhalla scoring and clinical questionnaire</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Correlations between Helbich-Bhalla scoring measured with MRI and CT and clinical questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between Helbich-Bhalla scoring and exacerbation rate</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Correlations between Helbich-Bhalla scoring measured with MRI and CT and exacerbation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between Helbich-Bhalla scoring and clinical pulmonary functional test</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Correlations between Helbich-Bhalla scoring measured with MRI and CT and clinical pulmonary functional test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>lung MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lung MRI without contrast injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>lung MRI</intervention_name>
    <description>lung MRI without contrast injection</description>
    <arm_group_label>lung MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female children (age ≥ 8 y.o) and adult patient with a diagnosis of cystic
             fibrosis provided by genetic and swear test older than 8 years. Subgroups of patients
             will be defined according to:

               -  age: younger or older 18y.o. We expect around 50% in different subgroups. In case
                  of, we reach 50% in one of these groups, patient recruitment will continue for
                  both groups until the expected number of patients in the study is reached.

               -  brand name of magnet: Siemens, General Electric or Philips

          -  new drugs use: association Ivacaftor/lumicaftor (OrkambiØ) or Ivacaftor only (Kalydeco
             Ø) ) We expect approximately 20% to 50% of patients treated

          -  Informed consent provided to the patient or/and to legal representative for adults and
             to parents for the children

          -  Patient concerned by articles L 1121-6, L 1121-7, and L 1121-8 (persons deprived of
             their liberty by a judicial or administrative decision, minors, persons of legal age
             who are the object of a legal protection measure or unable to express their consent)
             if the expected benefit for such persons justifies the foreseeable risk incurred

        Exclusion Criteria:

          -  patients without any social security or health insurance

          -  pregnant women

          -  Patients with previous pulmonary transplantation or planned for transplantation in the
             year following inclusion

          -  MRI contraindications:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francois Laurent, MD, PhD</last_name>
    <phone>+33 557656368</phone>
    <email>francois.laurent@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gael Dournes, MD, PhD</last_name>
    <phone>+33 557656542</phone>
    <email>gael.dournes@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaël Dournes, MD, PhD</last_name>
      <phone>+33 557656542</phone>
      <email>gael.dournes@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Rkia Achkir</last_name>
      <phone>+33 557623252</phone>
      <email>rkia.achkir@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Macey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Fayon, MD, PhD</last_name>
      <phone>+33 556799824</phone>
      <email>michael.fayon@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Francois Chateil, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Bassient, Md</last_name>
      <phone>+33 157022092</phone>
      <email>laurence.bassinet@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Alain Rahmouni, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilbert Ferretti, MD, PhD</last_name>
      <phone>33 476765241</phone>
      <email>gferretti@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Boubou Camara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine Remy-Jardin, MD</last_name>
      <phone>+33 32044 67 06</phone>
      <email>martine.remy@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine Reynaud-Gaubert, MD, PhD</last_name>
      <phone>+33 491966145</phone>
      <email>MartineLouise.REYNAUD@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Christophe Dubus, MD, PhD</last_name>
      <phone>04.91.96.60.49</phone>
      <email>JeanChristophe.DUBUS@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Petit, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Lenval</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corinne Boyer, MD</last_name>
      <phone>33 492030312</phone>
      <email>corinne.boyer@lenval.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand-Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harriet Corvol, MD, PhD</last_name>
      <phone>+33144736910</phone>
      <email>harriet.corvol@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Hubert Ducou-Lepointe, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker Enfant Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Sermet, MD, PhD</last_name>
      <phone>+33 144494887</phone>
      <email>isabelle.sermet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Grenet, MD</last_name>
      <phone>+33 146252582</phone>
      <email>d.grenet@hopital-foch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Bretonneau-Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Baptiste Morel, MD</last_name>
      <phone>+33 247473614</phone>
      <email>baptiste.morel@univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>November 23, 2017</last_update_submitted>
  <last_update_submitted_qc>November 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>CT</keyword>
  <keyword>MRI</keyword>
  <keyword>radiation dose</keyword>
  <keyword>contrast agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

